Last reviewed · How we verify
atazanavir/raltegravir
This combination blocks HIV protease and integrase enzymes to prevent viral replication and reduce viral load in HIV-infected patients.
This combination blocks HIV protease and integrase enzymes to prevent viral replication and reduce viral load in HIV-infected patients. Used for HIV-1 infection in treatment-experienced or treatment-naive adults.
At a glance
| Generic name | atazanavir/raltegravir |
|---|---|
| Sponsor | Community Research Initiative of New England |
| Drug class | Antiretroviral combination (protease inhibitor + integrase inhibitor) |
| Target | HIV protease and HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Atazanavir is a protease inhibitor that prevents HIV protease from cleaving viral polyproteins, blocking the maturation of infectious viral particles. Raltegravir is an integrase inhibitor that prevents HIV integrase from inserting viral DNA into the host genome. Together, they provide dual-mechanism antiretroviral activity against HIV-1.
Approved indications
- HIV-1 infection in treatment-experienced or treatment-naive adults
Common side effects
- Nausea
- Diarrhea
- Hyperbilirubinemia
- Headache
- Rash
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Population Pharmacokinetics of Antiretroviral in Children
- Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen (PHASE2, PHASE3)
- Kuwa Free! - Live Free! (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- atazanavir/raltegravir CI brief — competitive landscape report
- atazanavir/raltegravir updates RSS · CI watch RSS
- Community Research Initiative of New England portfolio CI